Merdury Biopharmaceutical Corporation (TPEX:6932)

Market Cap	3.35B -53.6%
Revenue (ttm)	246.00K -95.7%
Net Income	-70.59M
EPS	-0.17
Shares Out	418.44M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	504,351
Average Volume	434,350
Open	8.21
Previous Close	8.10
Day's Range	7.73 - 8.21
52-Week Range	4.95 - 15.90
Beta	-2.58
RSI	43.45
Earnings Date	Apr 2, 2026

About Merdury Biopharmaceutical

Merdury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan. The company develops StackDose platform, a drug development technology platform that integrates drug formulation, 3D powder printing, and hardware and software technologies to create drug-specific 3D printing production equipment, which can be used as a foundation for pharmaceutical companies to provide hosted services and in-house product development. Merdury Biopharmaceutical Corporation was founded in 2019 and is headquartered in New Taipei C...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2019
• Employees: 16
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6932

Financial Performance

In 2024, Merdury Biopharmaceutical's revenue was 4.96 million, an increase of 380.45% compared to the previous year's 1.03 million. Losses were -50.57 million, 15.4% more than in 2023.